Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 20,623 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Dysfunction Clear all
Completed Phase 1 Interventional

Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma

NCT00005580
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
bryostatin 1, fludarabine phosphate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2010 · Synced Oct 30, 2026, 11:48 AM EDT
Not yet recruiting Phase 4 Interventional

Opzelura Experience Study

NCT07661979
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ruxolitinib, ruxolitinib and an Eczema Action Plan
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 11:48 AM EDT
Recruiting Phase 1 Interventional

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

NCT06581562
View directory record Official record
Conditions
Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
Interventions
AB-101, Rituximab, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
IRIS Research and Development, LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 2 Interventional Results available

Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant

NCT00901225
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
Interventions
G-CSF plus Plerixafor
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 30, 2026, 11:48 AM EDT
Terminated Phase 1 Interventional

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

NCT02292225
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic, Lymphoma, Small Lymphocytic
Interventions
IPI-145 (duvelisib), Obinutuzumab
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

NCT01004991
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone, azacytidine
Biological · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 30, 2026, 11:48 AM EDT
Withdrawn No phase listed Observational

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

NCT03369574
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Asthma, Nasal Polyps
Interventions
Reslizumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 1Phase 2 Interventional

Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

NCT00572013
View directory record Official record
Conditions
Lymphoma
Interventions
Rituxan, BEAM, Autologous stem cell transplant
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 30, 2026, 11:48 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

NCT05006482
View directory record Official record
Conditions
Lymphoma, Malignant Solid Neoplasm
Interventions
Best Practice, Comprehensive Geriatric Assessment, Educational Intervention, Exercise Intervention, Questionnaire Administration, Tailored Intervention
Other · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
45
States / cities
Tuscaloosa, Alabama • Fremont, California • San Francisco, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 2 Interventional Results available

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

NCT01573624
View directory record Official record
Conditions
Asthma
Interventions
FF/GSK573719, FF, FF/VI
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 30, 2026, 11:48 AM EDT
Terminated Phase 2 Interventional Results available

Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)

NCT01946880
View directory record Official record
Conditions
Systemic Lupus Erythematosus, SLE
Interventions
Mycophenolate Mofetil, Hydroxychloroquine or Chloroquine, Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 2 Interventional

Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome

NCT00002479
View directory record Official record
Conditions
Lymphoma
Interventions
tretinoin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 30, 2026, 11:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis

NCT00407979
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 3 Interventional Results available

Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

NCT01328379
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Dalfampridine-ER 5mg, Dalfampridine-ER 10mg, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
70
States / cities
Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 30, 2026, 11:48 AM EDT
Terminated Phase 1 Interventional

Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693

NCT00493818
View directory record Official record
Conditions
Cancer
Interventions
GSK690693
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Indianapolis, Indiana • Detroit, Michigan • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Not applicable Interventional

Oral Probiotic Administration to Modulate the Airway Microbiome in Obese Asthmatic Subjects

NCT03157518
View directory record Official record
Conditions
Asthma
Interventions
Seeking Health Probiota Bifido
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 2 Interventional

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT00063713
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
VELCADE TM (bortezomib) for Injection
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
35
States / cities
Birmingham, Alabama • Berkeley, California • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2008 · Synced Oct 30, 2026, 11:48 AM EDT
Terminated Phase 2 Interventional Results available

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT02489123
View directory record Official record
Conditions
Ann Arbor Stage I Mantle Cell Lymphoma, Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Enzalutamide, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 30, 2026, 11:48 AM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

NCT06142396
View directory record Official record
Conditions
Multiple Myeloma, Renal Failure
Interventions
Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
Combination Product
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 4 Interventional Results available

Short-term B-cell Depletion in Relapsing Multiple Sclerosis

NCT03853746
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 4 Interventional

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

NCT07076446
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IgPro
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Centennial, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 2 Interventional Results available

Stress Management for Patients With Multiple Sclerosis

NCT00147446
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Individual Stress Management, Wait List Control
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Oct 30, 2026, 11:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

NCT02905227
View directory record Official record
Conditions
Migraine
Interventions
CVT-427 (zolmitriptan inhalation powder)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
North Dartmouth, Massachusetts • Lincoln, Nebraska • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 30, 2026, 11:48 AM EDT
Terminated Phase 1 Interventional

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

NCT05828589
View directory record Official record
Conditions
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Relapsed Follicular Lymphoma, Relapsed Marginal Zone Lymphoma, Relapse Diffuse Large B Cell Lymphoma, Relapsed Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Transformation, Refractory Diffuse Large B-cell Lymphoma, Transformed Non-Hodgkin Lymphoma
Interventions
BGB-21447
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Iowa City, Iowa • Waukee, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 11:48 AM EDT